At the virtual Scientific Sessions for the American Diabetes Association, Dr. Jennifer Sherr, MD, discussed the findings of a study of the Omnipod 5 automated insulin delivery system in very young children with type 1 diabetes.
Dr. Jennifer Sherr, MD, an associate professor in pediatrics at the Yale School of Medicine, led a discussion at the virtual Scientific Sessions for the American Diabetes Association on a study examining the benefits of the Omnipod 5 delivery system for very young children with type 1 diabetes. The study's objective was to evaluate the safety and efficacy of the Omnipod 5 system in children aged 2 to 5.9 years. The multicenter, single-arm outpatient study included 80 participants at 10 institutions across the United States. Participants had been diagnosed with type 1 diabetes, had an HbAc of less than 10% at the screening visit and had prior insulin therapy, such as continuous subcutaneous insulin infusion or multiple daily injection.
Sherr began her presentation by explaining how the Omnipod 5 System works. The delivery system communicates directly with Dexcom G6 sensor for a continuous glucose monitor. An algorithm is built into the pod, so that the insulin delivery can continue without the handheld controller nearby. The Omnipod 5 app is used to start and stop atuomated mode, deliver boluses, view data, and change settings. It includes customizable glucose targets, with a HypoProtect feature for times of elevated hypoglycemic risk (such as exercise).
After 3 months of use of the automatic insulin delivery (AID) system, 54% of the participants had an HbA1c of less than 7%, compared with 31% at baseline.
Additionally, there was improved sleep quality for parents and caregivers, with the percentage reporting overall sleep quality as "very good" or "fairly good" increasing fro 65% at baseline to 90% with the tubeless AID system. "Very bad" sleep quality, which was reported by 8.8% of the cohort at baseline, fell to 0% with the tubeless AID. Finally, there was no reported severe hypoglycemia or diabetic ketoacidosis during the 3-month AID phase of the study.
Sherr concluded that the Omnipodi 5 AID system was safe and performed well in very young children with T1D for 3 months at home.
Reference
1. Sherr, J. Evaluation of the Omnipod 5 automated insulin delivery system in very young children with type 1 diabetes (T1D). American Diabetes Association Scientific Sessions 2021; June 26, 2021; virtual. Accessed June 26, 2021.
Fluoxetine helps refractory nocturnal enuresis but not for long
March 29th 2023A 12-week study in Egypt of the efficacy of fluoxetine (a selective serotonin reuptake inhibitor) in children with treatment-refractory nocturnal enuresis (NE) found that though the treatment achieved a good initial response, it was not sustainable.
Meet the Board: Vivian P. Hernandez-Trujillo, MD, FAAP, FAAAAI, FACAAI
May 20th 2022Contemporary Pediatrics sat down with one of our newest editorial advisory board members: Vivian P. Hernandez-Trujillo, MD, FAAP, FAAAAI, FACAAI to discuss what led to her career in medicine and what she thinks the future holds for pediatrics.
Are some patients predisposed to avascular necrosis after hip surgery?
March 14th 2023Although avascular necrosis (AVN) is believed to be an iatrogenic complication following treatment of developmental dysplasia of the hip, an investigation in China found 2 characteristics associated with the condition: the likelihood of AVN increases with both the grade of dislocation and of underdevelopment of the ossific nucleus.
Meet the board: Jessica L. Peck, DNP, APRN, CPNP-PC, CNE, CNL, FAANP, FAAN
April 22nd 2022In the latest episode of our podcast series, Jessica L. Peck, DNP, APRN, CPNP-PC, CNE, CNL, FAANP, FAAN shares why she got into medicine, the myths of pediatric, and what the future may hold for the specialty.